Amneal Pharmaceuticals (AMRX) Gains from Investment Securities (2021 - 2024)
Amneal Pharmaceuticals (AMRX) posted quarterly Gains from Investment Securities of $930000.0 for Q4 2024, up 106.78% year-over-year from $449746.0 in Q1 2024, and up 190.29% quarter-over-quarter from -$1.0 million in Q3 2024.
Amneal Pharmaceuticals (AMRX) Gains from Investment Securities (2021 - 2024) Analysis & Trends
Amneal Pharmaceuticals' Gains from Investment Securities history runs 4 years deep, the most recent figure standing at $930000.0 for Q4 2024.
- In Q4 2024, Gains from Investment Securities rose 106.78% year-over-year to $930000.0; the TTM figure through Sep 2024 stood at -$14.6 million (down 1117.37% YoY), while the FY2023 annual figure was -$14.5 million, down 2083.17% from the prior year.
- Gains from Investment Securities for Q4 2024 stood at $930000.0, up from -$1.0 million in the prior quarter.
- The five-year high for Gains from Investment Securities was $3.1 million in Q3 2023, with the low at -$13.7 million in Q4 2023.
- The 4-year median for Gains from Investment Securities is $100000.0 (2024), against an average of -$1.0 million.
- The sharpest annual moves came in 2022 and 2023: Gains from Investment Securities jumped 2326.0% in 2022, then slumped 2257.04% in 2023.
- Amneal Pharmaceuticals' Gains from Investment Securities stood at -$100000.0 in 2021, then surged by 2326.0% to $2.2 million in 2022, then slumped by 715.9% to -$13.7 million in 2023, then jumped by 106.78% to $930000.0 in 2024.
- Business Quant data shows AMRX's Gains from Investment Securities at $930000.0 in Q4 2024, -$1.0 million in Q3 2024, and $100000.0 in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - |
| 10 | Amneal Pharmaceuticals | 5.72 Bn | 5.59 Bn | 334.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 930,000.00 |
| Dec 31, 2024 | 930,000.00 |
| Sep 30, 2024 | -1.03 Mn |
| Sep 30, 2024 | -1.03 Mn |
| Mar 31, 2024 | 100,000.00 |
| Mar 31, 2024 | 100,000.00 |
| Dec 31, 2023 | -13.71 Mn |
| Dec 31, 2023 | -13.71 Mn |
| Sep 30, 2023 | 3.12 Mn |
| Sep 30, 2023 | 3.12 Mn |
| Jun 30, 2023 | -6.36 Mn |
| Jun 30, 2023 | -6.36 Mn |
| Mar 31, 2023 | 2.46 Mn |
| Mar 31, 2023 | 2.46 Mn |
| Dec 31, 2022 | 2.23 Mn |
| Dec 31, 2022 | 2.23 Mn |
| Sep 30, 2022 | -1.43 Mn |
| Sep 30, 2022 | -1.43 Mn |
| Jun 30, 2022 | -270,000.00 |
| Jun 30, 2022 | -270,000.00 |